Elizabeth B. Andrews, PhD, MPH will be participating on a six member panel at the DIA/FDA/PhRMA Drug Safety Conference in Arlington, VA on October 15, 2008.
The panel will discuss concrete ways to implement prospective planning of safety evaluation during different phases of a drug’s lifecycle. The discussion will also reflect on key concepts and learnings from the two days of the conference.
Elizabeth Andrews, PhD, is the Vice President of Pharmacoepidemiology and Risk Management at RTI-Health Solutions. She provides consultation for pharmaceutical companies and the US Food and Drug Administration on therapeutic risk management, and she directs research programs that evaluate drug safety and compliance with prescribing and treatment guidelines. She oversees the conduct of large, prospective patient registries, Web-based surveys, and studies using large prospective databases. Dr. Andrews currently serves as principal investigator on two large risk management programs. Her primary research focus has been on studies of disease natural history, treatment patterns, and drug safety. Her experience has spanned most therapeutic areas, though she has worked extensively in the areas of HIV and sexually transmitted diseases; reproductive health, birth defects, and neonatal health; asthma and COPD; and irritable bowel syndrome. Dr. Andrews is involved in the design of observational research programs within RTI-HS to assure that the methods chosen provide a robust and cost-effective approach to address the study questions and to assure appropriate linkages are forged with academic and governmental partners.
Previously, Dr. Andrews was Vice President, Worldwide Epidemiology, at GlaxoSmithKline and conducted epidemiologic research in a variety of therapeutic areas, including rheumatoid arthritis, genital herpes, HIV, asthma, migraine, and irritable bowel syndrome. She initiated the first pharmaceutical pregnancy registry, the Acyclovir Pregnancy Registry, and multiple registries for other medications.
She is a Fellow and Past President of the International Society for Pharmacoepidemiology, a member of the editorial board of the Journal of Pharmacoepidemiology and Drug Safety, and co-editor of Pharmacovigilance. She is an Adjunct Associate Professor of the University of North Carolina School of Public Health and School of Pharmacy, a senior consultant and investigator with the UNC Center for Education and Research on Therapeutics, and a consultant to the FDA in epidemiology and risk management.
Please contact Elizabeth directly if you plan to attend the conference and would like to pre-arrange a meeting time with her.